MX2007011975A - Human glp-1 mimetibodies, compositions, methods and uses. - Google Patents

Human glp-1 mimetibodies, compositions, methods and uses.

Info

Publication number
MX2007011975A
MX2007011975A MX2007011975A MX2007011975A MX2007011975A MX 2007011975 A MX2007011975 A MX 2007011975A MX 2007011975 A MX2007011975 A MX 2007011975A MX 2007011975 A MX2007011975 A MX 2007011975A MX 2007011975 A MX2007011975 A MX 2007011975A
Authority
MX
Mexico
Prior art keywords
methods
glp
compositions
mimetibody
mimetibodies
Prior art date
Application number
MX2007011975A
Other languages
Spanish (es)
Inventor
Kristen Picha
Karyn T O'neil
Original Assignee
Johnson & Johnson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson filed Critical Johnson & Johnson
Publication of MX2007011975A publication Critical patent/MX2007011975A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to at least one novel human GLP-1 mimetibody or specified portion or variant, including isolated nucleic acids that encode at least one GLP-1 mimetibody or specified portion or variant, GLP-1 mimetibody or specified portion or variants, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
MX2007011975A 2005-03-28 2005-12-22 Human glp-1 mimetibodies, compositions, methods and uses. MX2007011975A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2005097175 2005-03-28
PCT/US2005/046884 WO2007081302A2 (en) 2005-03-28 2005-12-22 Human glp-1 mimetibodies, compositions, methods and uses

Publications (1)

Publication Number Publication Date
MX2007011975A true MX2007011975A (en) 2008-03-14

Family

ID=38256744

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007011975A MX2007011975A (en) 2005-03-28 2005-12-22 Human glp-1 mimetibodies, compositions, methods and uses.

Country Status (12)

Country Link
EP (1) EP1871811A4 (en)
JP (1) JP2008546373A (en)
KR (1) KR20080005378A (en)
CN (1) CN101389346A (en)
AU (1) AU2005339797A1 (en)
BR (1) BRPI0520168A2 (en)
CA (1) CA2603359A1 (en)
CR (1) CR9481A (en)
IL (1) IL186307A0 (en)
MX (1) MX2007011975A (en)
NO (1) NO20075272L (en)
WO (1) WO2007081302A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200843794A (en) 2006-12-21 2008-11-16 Centocor Inc Use of long-acting GLP-1 receptor agonists to improve insulin sensitivity and lipid profiles
CN111574583B (en) * 2020-04-10 2021-06-25 上海海路生物技术有限公司 Protein renaturation reagent and its application

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000046380A2 (en) * 1999-02-08 2000-08-10 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
SI1724284T1 (en) * 2000-12-07 2009-12-31 Lilly Co Eli GLP-1 fusion proteins
KR20050033563A (en) * 2002-06-28 2005-04-12 센토코 인코포레이티드 Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses
EP1545608A4 (en) * 2002-06-28 2006-09-13 Centocor Inc Mammalian ch1 deleted mimetibodies, compositions, methods and uses
US20050033029A1 (en) * 2003-06-30 2005-02-10 Jin Lu Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
WO2005097175A2 (en) * 2004-03-31 2005-10-20 Centocor, Inc. Human glp-1 mimetibodies, compositions, methods and uses

Also Published As

Publication number Publication date
NO20075272L (en) 2007-12-28
BRPI0520168A2 (en) 2009-04-22
CA2603359A1 (en) 2007-07-19
EP1871811A2 (en) 2008-01-02
WO2007081302A2 (en) 2007-07-19
KR20080005378A (en) 2008-01-11
WO2007081302A3 (en) 2008-11-13
IL186307A0 (en) 2008-01-20
EP1871811A4 (en) 2009-07-22
AU2005339797A1 (en) 2007-07-19
CN101389346A (en) 2009-03-18
CR9481A (en) 2009-01-14
JP2008546373A (en) 2008-12-25

Similar Documents

Publication Publication Date Title
SG151315A1 (en) Human glp-1 mimetibodies, compositions, methods and uses
WO2008011446A3 (en) Human glp-1 mimetibodies, compositions, methods and uses
MX2007007602A (en) Glp-1 agonists, compositions, methods and uses.
WO2005081687A3 (en) Human hinge core mimetibodies, compositions, methods and uses
WO2004002417A3 (en) Mammalian ch1 deleted mimetibodies, compositions, methods and uses
UA101301C2 (en) Isolated il-23pl9 antibody and use thereof
WO2003084477A3 (en) Mammalian cdr mimetibodies, compositions, methods and uses
WO2005032460A3 (en) Human epo mimetic hinge core mimetibodies, compositions, methods and uses
MX2007014610A (en) Anti- mcp-1 antibodies, compositions, methods and uses.
MX2010004179A (en) Human anti-amyloid antibodies, compositions, methods and uses.
LUC00121I1 (en)
WO2006085961A3 (en) Anti-mcp-1 antibodies, compositions, methods and uses
WO2006124451A3 (en) Anti-il-13 antibodies, compositions, methods and uses
WO2005062881A3 (en) Gene therapy using transposon-based vectors
MY161415A (en) A homeopathic formulation
WO2005028511A3 (en) Anti-amyloid antibodies, compositions, methods and uses
HK1118458A1 (en) Anti-il-23 antibodies, compositions, methods and uses
MY142835A (en) Anti-il-6 antibodies, compositions, methods and uses
MY141215A (en) Il-23p40 specific immunoglobulin derived proteins, compositions, epitopes, method and uses
WO2005112597A3 (en) Transgenic plants expressing intein modified proteins and associated processes for bio-pharmaceutical production
TW200508246A (en) Anti-dengue virus antibodies, compositions, methods and uses
WO2007076319A3 (en) Human glp-1 mimetibodies and compositions for treating obesity and related disorders, methods and uses
WO2006039638A3 (en) Treating renal cell carcinoma with an anti-tnf human antibody or fragment
MX2007011975A (en) Human glp-1 mimetibodies, compositions, methods and uses.
WO2006110507A3 (en) Plant phytase genes and methods of use

Legal Events

Date Code Title Description
FA Abandonment or withdrawal